Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (not Scinai Immunotherapeutics Ltd.) covers the month of April 2022, with a filing date of April 4, 2022. The document serves as a notice to shareholders regarding the scheduling of the Company's Annual General Meeting.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a corporate governance notice and does not contain financial statements or performance data.
Material Changes
No material financial changes versus a prior comparable period are reported in this document.
Guidance, Outlook, and Corporate Actions
- Annual General Meeting: The Company has scheduled its Annual General Meeting of Shareholders for May 16, 2022, at 4:00 p.m. Israel time.
- Location: The meeting will be held at the offices of Gross & Co., One Azrieli Center, Tel Aviv, Israel.
- Exhibits: A Notice of the Annual General Meeting is included as Exhibit 99.1 and incorporated by reference into the Company's Form F-3 and Form S-8 registration statements.
Investor Verification Checklist
- Verify the correct registrant name is BiondVax Pharmaceuticals Ltd., as the input metadata referenced Scinai Immunotherapeutics Ltd.
- Confirm the date, time, and physical location of the Annual General Meeting (May 16, 2022, Tel Aviv).
- Review the attached Notice of Annual General Meeting (Exhibit 99.1) for specific agenda items and voting procedures.
- Note that this filing contains no financial data; refer to the most recent Form 20-F for financial metrics.